(EKTA-B) Elekta (publ) - Ratings and Ratios

Elekta AB (publ) is a Swedish medical technology company specializing in innovative clinical solutions for cancer treatment and brain disorders. The companys comprehensive product portfolio includes radiation therapy, stereotactic radiosurgery, brachytherapy, and neurosurgery solutions, as well as software suites and veterinary radiation therapy products. With a strong focus on precision and personalized care, Elektas products, such as Elekta Unity and Leksell Gamma Knife Icon, enable healthcare professionals to deliver targeted treatments with improved accuracy and efficiency.

Analyzing the companys technical data, we observe that the stock has experienced a decline from its 52-week high of 82.88 SEK, currently trading at 49.40 SEK. The short-term moving averages (SMA20 and SMA50) indicate a relatively stable price level around 50.70 SEK, while the long-term SMA200 suggests a significant support level at 60.30 SEK. The Average True Range (ATR) of 1.51 SEK, equivalent to 3.05% volatility, implies a moderate level of price fluctuations. Based on these technical indicators, we can anticipate a potential rebound in the stock price if it stabilizes above the 50.70 SEK level.

From a fundamental perspective, Elektas market capitalization stands at 19.1 billion SEK, with a price-to-earnings ratio of 18.38 and a forward P/E of 12.02. The companys return on equity (RoE) is 9.73%, indicating a relatively stable profitability profile. Considering the industrys growth prospects and Elektas diversified product portfolio, we can forecast a potential increase in revenue and earnings. By combining the technical and fundamental analysis, we predict that Elektas stock price may experience a moderate recovery in the short term, potentially reaching 55-60 SEK within the next 6-12 months, driven by the companys strong product offerings and improving profitability.

To achieve this forecast, Elekta will need to continue innovating and expanding its product portfolio, while maintaining its focus on precision and personalized care. The companys ability to adapt to changing market conditions and regulatory requirements will be crucial in driving future growth. As the demand for cancer treatment and brain disorder solutions continues to rise, Elekta is well-positioned to capitalize on this trend, driven by its comprehensive product portfolio and commitment to innovation.